PENG Lan, BAI Ting, ZHONG Yun, KANG Yan, CHEN Dali
2025, 33(8): 1866.
To evaluate the distinguish value of the median multiple of the soluble vascular endothelial growth factor receptor-1 (sFlt-1)/the placental growth factor (PlGF) ratio of pregnant women with suspected preeclampsia (PE) for predicting their preeclampsia and small for gestational age fetuses complication with small for gestational age (SGA) fetuses. Methods: A total of 967 single pregnant women with suspected PE who underwent regular prenatal care after 20 gestational weeks in the hospital from July 2022 to July 2023 were included in this study. The baseline information, such as the conventional clinical and laboratory results, and the levels of the sFlt-1 and PLGF,
and the pregnant outcomes after follow-up to delivery of the women were collected. These women were divided into four groups according to their onset of PE and/or SGA, which including group A (women with PE complication with SGA fetus), group B (women with PE), group C (women with SGA fetus) and control group (women without PE and SGA). The baseline information, the levels of sFlt-1 and PLGF, the MoM of sFlt-1/PLGF and the maternal and infant outcomes of the women were compared among the four groups. Receiver operating characteristic curve (ROC) was adopted to analyze the distinguish values of the levels of sFlt-1 and PLGF, the MoM and absolute values of sFlt-1/PLGF, and the multi-parameter prediction model of the pregnant women with suspected PE for predicting their PE and SGA. The survival curves were used to analyze the hazard ratio of MoM of sFlt-1/PlGF of the women for their delivery immediately. Results: The women in group A had the highest MoM (P25, P75) of sFlt-1 level of 9.14 (2.91, 16.86) and sFlt-1/PLGF ratio of 110.27 (14.29, 360.63), and had the lowest MoM (P25, P75) of the PLGF level of 0.12 (0.06, 0.30), and all which of the women in group A were significantly different from those of the women in the other three groups (P<0.001). The maternal and infant outcomes of the women in group A were the worst among the four groups (P<0.001). The sFlt-1/PLGF MoM value of the pregnant women had the excellent predictive discrimination ability for their PE complication with SGA (AUC=0.942), and which was superior to that of the prediction model established based on the other forms of angiogenesis factors and the routine clinical and laboratory indicators of the women (AUC=0.927), with the cutoff value, the sensitivity, the specificity, the positive predictive value, the negative predictive value and the Youden index of 11.788, 80%, 92.6%, 45.53%, 98.34%, and 0.726. The median of the interval time from enrollment to delivery of the women was 2 weeks when their sFlt-1/PLGF MoM ≥11.788, and the median of the interval time from enrollment to delivery of the women was 10 weeks when their sFlt-1/PLGF MoM <11.788, and which had significant difference in the interval time from enrollment to delivery between the women with sFlt-1/PLGF MoM ≥11.788 and the women with sFlt-1/PLGF MoM <11.788 (Log Rank χ2=173.179, P<0.001). Conclusion: The MoM of sFlt-1/PLGF of the pregnant women with the suspected PE has excellent predict and distinguish ability for their PE complication with SGA, and it is even better than the multi-parameter prediction model established based on the conventional clinical and laboratory indicators of the women, and which can be used as an effective prediction tool for the PE and SGA of the pregnant women. When the sFlt-1/PLGF MoM of the women was ≥11.788, it indicates that there is the high risk of delivery of the women within 2 weeks, so it is needs to strengthen the monitoring frequency and the timely clinical intervention.